Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53

Cellular Physiology and Biochemistry

Volumn 39, Issue 5, 2016, Pages 2088-2098

  Tian, Xin ^a   Dai, Shundong ^a,b   Sun, Jing ^c   Jiang, Shenyi ^a   Sui, Chengguang ^a   Meng, Fandong ^a   Li, Yan ^a   Fu, Liye ^a   Jiang, Tao ^a   Wang, Yang ^a   Su, Jia ^a   Jiang, Youhong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Institute of Pathology and Pathophysiology   (China)

^c LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

MDM2; p53; Rapamycin; Renal cancer

Indexed keywords

LIGASE INHIBITOR; MESSENGER RNA; MI 319; PROTEIN MDM2; PROTEIN P53; RAPAMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG COMBINATION; INDOLE DERIVATIVE; MDM2 PROTEIN, MOUSE; SMALL INTERFERING RNA; SPIRO COMPOUND;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL CANCER CELL LINE; UPREGULATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; INJECTIONS, SUBCUTANEOUS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; SPIRO COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84994153107     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000447904     Document Type: Article

References (22)

1. Laplante M, Sabatini DM: MTOR signaling in growth control and disease. Cell 2012;149:274-293.
2. Huang K, Fingar DC: Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol 2014;36C:79-90.
3. Ballou LM, Lin RZ: Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008;1:27-36.
4. Seto B: Rapamycin and mTOR: A serendipitous discovery and implications for breast cancer. Clin Transl Med 2012;1:29.
5. Huang S, Bjornsti MA, Houghton PJ: Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003;2:222-232.
6. Yoon SO, Roux PP: Rapamycin resistance: MTORC1 substrates hold some of the answers. Curr Biol 2013;23:R880-R883.
7. Dennis PB, Pullen N, Kozma SC, Thomas G: The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 1996;16:6242-6251.
8. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC: Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. Embo J 1998;17:6649-6659.
9. Koide H, Asai T, Furuya K, Tsuzuku T, Kato H, Dewa T, Nango M, Maeda N, Oku N: Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector. Biol Pharm Bull 2011;34:602-608.
10. Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T, Taniguchi S: Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol 2010;37:1001-1010.
11. Beamish H, Williams R, Chen P, Khanna KK, Hobson K, Watters D, Shiloh Y, Lavin M: Rapamycin resistance in ataxia-telangiectasia. Oncogene 1996;13:963-970.
12. Wade M, Li YC, Wahl GM: MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83-96.
13. Sun H, Xin J, Lu Z, Wang N, Liu N, Guo Q: Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer. Cell Physiol Biochem 2013;32:1528-1540.
14. Liu J, Zhang X, Liu A, Liu S, Zhang L, Wu B, Hu Q: Berberine induces apoptosis in p53-null leukemia cells by down-regulating XIAP at the post-transcriptional level. Cell Physiol Biochem 2013;32:1213-1224.
15. Manfredi JJ: The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010;24:1580-1589.
16. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM: P53 as a target for the treatment of cancer. Cancer Treat Rev 2014;40:1153-1160.
17. Du W, Yi Y, Zhang H, Bergholz J, Wu J, Ying H, Zhang Y, Xiao ZX: Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy. PLoS One 2013;8:e63179.
18. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM: MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 2010;46:1122-1131.
19. Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM: An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer 2009;8:115.
20. Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-446.
21. Kao CL, Hsu HS, Chen HW, Cheng TH: Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells. Cancer Lett 2009;286:250-259.
22. O'Keefe K, Li H, Zhang Y: Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol 2003;23:6396-6405.